Sci Data. 2017 Jul 19;4:170091. doi: 10.1038/sdata.2017.91.
Ehwang Song, Yuqian Gao, Chaochao Wu, Tujin Shi, Song Nie, Thomas L Fillmore, Athena A Schepmoes, Marina A Gritsenko, Wei-Jun Qian, Richard D Smith, Karin D Rodland, Tao Liu
PMCID: PMC5516542 DOI: 10.1038/sdata.2017.91
Mass spectrometry (MS) based targeted proteomic methods such as selected reaction monitoring (SRM) are emerging as a promising tool for verification of candidate proteins in biological and biomedical applications. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the National Cancer Institute has investigated the standardization and analytical validation of the SRM assays and demonstrated robust analytical performance on different instruments across different laboratories. An Assay Portal has also been established by CPTAC to provide the research community a resource consisting of large sets of targeted MS-based assays, and a depository to share assays publicly. Herein, we report the development of 98 SRM assays that have been thoroughly characterized according to the CPTAC Assay Characterization Guidance Document; 37 of these passed all five experimental tests. The assays cover 70 proteins previously identified at the protein level in ovarian tumors. The experiments, methods and results for characterizing these SRM assays for their MS response, repeatability, selectivity, stability, and endogenous detection are described in detail. Data are available via PeptideAtlas, Panorama and the CPTAC Assay Portal.